Crispr Therapeutics Stock Been: A Roller-Coaster Year Unpacked
CRISPR Therapeutics stock has zigzagged all year, driven by pipeline milestones, regulatory updates, and funding need...
A straightforward take on whether SP 500 or balanced funds fit better for retirement, covering growth potential, risk, and suitability.
25,481 articlesCRISPR Therapeutics stock has zigzagged all year, driven by pipeline milestones, regulatory updates, and funding need...
A massive stockpile of used nuclear fuel sits in storage, but new tech could turn that waste into energy. This invest...
Tension in the Middle East threatens to throttle energy flows, with oil and gas markets reacting as investors reasses...
A headline about Palantir and a high-stakes defense AI plan could reshape risk and opportunity. This guide breaks dow...
A wave of crypto venues is turning macro data and oil into around-the-clock trading products. Perpetual futures and p...
When a CEO steps up with a sizable open-market purchase, investors take note. We unpack what McGraw Hill's 22,000-sha...
Official Q2 data show china’s economy slows weakest in over three years, with 4.3% annualized growth as domestic dema...
Bitcoin remains above $66,000 as March begins, with analysts weighing a bitcoin high-stakes march: $120k scenario ami...
A CFO sold a sizable block of Perdoceo Education shares during a year of strong stock gains. This guide explains what...
The Strategic Petroleum Reserve sits near a 40-year low, yet Wall Street focuses on production and demand signals rat...
Retail buzz around Celsius, Chewy, and Estée Lauder is pulsing through markets as earnings shape the near-term outloo...
Oracle’s stock has fallen from its AI-redemption peak as management bets heavily on data-center compute. Analysts are...